KR890009922A - 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온 - Google Patents

아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온 Download PDF

Info

Publication number
KR890009922A
KR890009922A KR1019880015992A KR880015992A KR890009922A KR 890009922 A KR890009922 A KR 890009922A KR 1019880015992 A KR1019880015992 A KR 1019880015992A KR 880015992 A KR880015992 A KR 880015992A KR 890009922 A KR890009922 A KR 890009922A
Authority
KR
South Korea
Prior art keywords
compound
formula
dione
thiazolidine
benzopyran
Prior art date
Application number
KR1019880015992A
Other languages
English (en)
Other versions
KR900006993B1 (ko
Inventor
노만 크럽 마이클
칼훈 스윈델 아키
Original Assignee
윌리암 데이비스 헌
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 헌, 화이자 인코포레이티드 filed Critical 윌리암 데이비스 헌
Publication of KR890009922A publication Critical patent/KR890009922A/ko
Application granted granted Critical
Publication of KR900006993B1 publication Critical patent/KR900006993B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음

Description

아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질 -3, 4-디하이드로-2H-벤조피 란-6-일)메틸]티아졸리딘-2, 4-디온
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 포유동물의 혈청 클레스테롤 수준을 낮추기 위한, 약제 조성물을 제조하기 위한 하기 구조식(I}의 화합물 또는 약리적으로 허용가능한 그의 양이온 염의 용도
  2. 제1항에 있어서, 약제조셩물이 경구투여에 적합한 구조식(I)의 화합물 또는 약리적으로 허용가능한 그의 양이온염의 용도.
  3. 제2항에 있어서, 화합물이 구조식(I)의 화합물의 나트륨 염인 구조식(I)의 화합물의 나트륨 염인 구조식(I)의 화합물의 용도.
  4. 제1항에 있어서, 약제조성물이 비경구투여에 적합한 구조식(I)의 화합물 또는 약리적으로 허용가능한 그의 양이온 염의 용도.
  5. 제4항에 있어서, 화합물이 구조식(I)의 나트륩 염인 구조식(I) 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880015992A 1987-12-02 1988-12-01 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온 KR900006993B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/127,858 US4798835A (en) 1987-12-02 1987-12-02 dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US127,858 1987-12-02
US127858 1987-12-02

Publications (2)

Publication Number Publication Date
KR890009922A true KR890009922A (ko) 1989-08-04
KR900006993B1 KR900006993B1 (ko) 1990-09-25

Family

ID=22432331

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880015992A KR900006993B1 (ko) 1987-12-02 1988-12-01 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온

Country Status (16)

Country Link
US (1) US4798835A (ko)
EP (1) EP0319288B1 (ko)
JP (1) JPH01186883A (ko)
KR (1) KR900006993B1 (ko)
AT (1) ATE81456T1 (ko)
AU (1) AU604176B2 (ko)
CA (1) CA1313139C (ko)
DE (1) DE3875324T2 (ko)
DK (1) DK670988A (ko)
HU (1) HU204433B (ko)
IE (1) IE883600L (ko)
IL (1) IL88513A (ko)
MY (1) MY103498A (ko)
PH (1) PH24873A (ko)
PT (1) PT89123B (ko)
ZA (1) ZA888968B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
ATE144142T1 (de) * 1991-01-10 1996-11-15 Transcend Therapeutics Inc Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) * 1991-09-26 1999-02-02 The Regents Of The University Of California Calcium antagonists for treatment of vascular restenosis
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物

Also Published As

Publication number Publication date
JPH01186883A (ja) 1989-07-26
CA1313139C (en) 1993-01-26
EP0319288B1 (en) 1992-10-14
DK670988D0 (da) 1988-12-01
MY103498A (en) 1993-06-30
US4798835A (en) 1989-01-17
DK670988A (da) 1989-07-24
ZA888968B (en) 1990-07-25
HUT54045A (en) 1991-01-28
KR900006993B1 (ko) 1990-09-25
ATE81456T1 (de) 1992-10-15
PT89123A (pt) 1989-12-29
PH24873A (en) 1990-12-26
IE883600L (en) 1989-06-02
DE3875324T2 (de) 1993-02-25
AU2647188A (en) 1989-06-08
EP0319288A3 (en) 1990-12-27
DE3875324D1 (de) 1992-11-19
EP0319288A2 (en) 1989-06-07
IL88513A0 (en) 1989-06-30
IL88513A (en) 1994-04-12
PT89123B (pt) 1993-09-30
AU604176B2 (en) 1990-12-06
HU204433B (en) 1992-01-28
JPH0460582B2 (ko) 1992-09-28

Similar Documents

Publication Publication Date Title
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
KR900014367A (ko) 피롤리딘 유도체
KR970027098A (ko) 프로피오페논 유도체 및 이의 제조 방법
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR890016966A (ko) 신규 항바이러스제
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
KR970025615A (ko) 암 전이 억제제
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR890009922A (ko) 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR910004191A (ko) 신질환치료제
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR860008973A (ko) 2-피롤리돈 유도체
OA09022A (fr) Nouveaux dérivés flavonoides pipérazyl-2 oxo-é éthylànes substitués, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
KR900001715A (ko) Bu-3608 유도체
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR900012925A (ko) 인돌 유도체
KR900014385A (ko) 제약학적 치료
KR880004810A (ko) 소화성 궤양 치료제
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
KR890006234A (ko) 고혈압 및 심부전증 치료제
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
KR900701273A (ko) 진토성 에르골린 유도체

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930916

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee